Eliquis at $280/Month on GoodRx vs. $47/Month Through Part D: Why Pharmacy Coupons Don't Count Toward Medicare's $2,000 Drug Cap
The Pharmacy Counter Trap That Costs Medicare Beneficiaries Thousands
Patricia is 72, has atrial fibrillation, and takes Eliquis 5mg twice daily to prevent stroke. She also takes atorvastatin 40mg for cholesterol and lisinopril 10mg for blood pressure. Her Part D renewal landed in January and, like most people, she didn't review it closely. By March, her Eliquis copay had crept to $140/month. A friend mentioned she could save money using a pharmacy coupon app — and sure enough, GoodRx showed Eliquis at $278 at her local CVS.
Patricia's friend uses GoodRx for metformin, where the coupon saves her a couple of dollars on a $6 drug. That math doesn't apply to Eliquis. And for a Medicare beneficiary specifically, reaching for a coupon instead of her Part D coverage could cost Patricia nearly $1,900 more per year — even though the number on her phone screen looks lower.
Here's why.
What TrumpRx Does — And Doesn't Do — for Medicare Beneficiaries
The White House's TrumpRx initiative, reported on in depth by KFF Health News in both "Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up." and "That Discount at the Pharmacy Counter May Pack Hidden Costs," operates largely by connecting patients with manufacturer discount programs and third-party coupons. The idea is to lower the sticker price people see at the pharmacy counter.
The problem, as KFF Health News detailed, is that for insured patients — and especially for Medicare Part D enrollees — using these coupons instead of your insurance is often a losing financial move. The reason comes down to one mechanism that almost nobody explains clearly at the pharmacy window:
When you pay for a covered drug using a coupon or discount card instead of your Part D insurance, that payment does not count toward your Part D deductible or your True Out-of-Pocket (TrOOP) costs.
TrOOP is the tally Medicare keeps of what you actually pay through your Part D benefit — your deductible, your copays, your coinsurance. In 2026, once your TrOOP reaches $2,000, your Part D plan covers 100% of your remaining covered drug costs for the rest of the year.
Pay with GoodRx and bypass your insurance? You spent real money on a real drug, but Medicare didn't see it. You get zero credit toward the cap. Every coupon payment is a dead-end in terms of building toward that $2,000 ceiling.
KFF Health News put it bluntly: "the share of Americans his policies will likely help remains slim." If you already have a solid Part D plan covering an IRA-negotiated drug like Eliquis, bypassing your insurance for a coupon is almost certainly making you poorer, not richer.
The Full-Year Math on Eliquis: Coupon vs. Plan A vs. Plan B
Eliquis (apixaban) became a Medicare-negotiated drug under the Inflation Reduction Act in 2026, with a Maximum Fair Price of approximately $231/month for a 60-tablet supply of 5mg. That negotiated price is the basis your Part D plan uses when calculating your copay. Here's what Patricia's total annual cost looks like across three paths:
| Approach | Monthly Drug Cost | Annual Drug OOP | Counts Toward $2,000 Cap? | Annual Premium | Total Annual Cost |
|---|---|---|---|---|---|
| GoodRx coupon (cash, bypasses Part D) | $278 | $3,336 | No | $0 | $3,336 |
| Part D Plan A — $33/mo premium, preferred pharmacy, Tier 3 preferred brand | $47 | $590 deductible + ($47 × ~10 mo) = $1,060 | Yes | $396 | $1,456 |
| Part D Plan B — $0 premium, non-preferred pharmacy, Tier 4 | $120 | $590 deductible + ($120 × ~10 mo) = $1,790 | Yes | $0 | $1,790 |
Atorvastatin and lisinopril are Tier 1 generics on both plans — typically deductible-exempt and $0–$3/month — so they don't change the comparison materially.
The GoodRx coupon costs $1,880 more per year than Plan A. Even the worse Part D option — the $0-premium plan with higher copays — beats the coupon by $1,546 annually.
This is the kind of side-by-side annual math Pelandri runs for your actual drug list — because these numbers shift completely when you add a second brand drug, change pharmacies, or move to a different ZIP code.
When a Coupon Actually Makes Sense (and When It Doesn't)
Not every drug behaves like Eliquis. There are narrow situations where a coupon legitimately beats your Part D plan:
Coupons may win when:
- The drug is not on your formulary (not covered at all by your plan)
- You're on a Tier 5 specialty drug with 25–33% coinsurance and no realistic path to hitting the $2,000 cap
- The drug is a cheap generic ($4–$10/month) and the coupon saves marginally — the OOP cap impact is negligible anyway
- You've already hit your $2,000 TrOOP cap for the year and the coupon is cheaper at that point (rare edge case)
Coupons will cost you when:
- Your drug is an IRA-negotiated medication (Eliquis, Jardiance, Entresto, Imbruvica, and others)
- You take one or more expensive brand drugs and are on track to approach the $2,000 cap
- Your plan already places the drug on a preferred tier with a competitive copay
- You take multiple brand drugs whose combined TrOOP spending adds up over a year
Here's how this plays out for Patricia's complete drug list:
| Drug | GoodRx Price | Plan A Copay | Plan B Copay | TrOOP Credit on Plan A |
|---|---|---|---|---|
| Eliquis 5mg (60 tabs) | $278/mo | $47/mo | $120/mo | Yes |
| Atorvastatin 40mg (30 tabs) | $6/mo | $0/mo (Tier 1) | $0/mo (Tier 1) | Yes |
| Lisinopril 10mg (30 tabs) | $4/mo | $0/mo (Tier 1) | $3/mo (Tier 1) | Yes |
| Annual total (incl. premium) | $3,456 | $1,456 | $1,790 | — |
If Patricia adds a second expensive brand drug — say, her doctor starts her on Jardiance for cardiovascular protection — the TrOOP credit becomes even more valuable. We modeled exactly this scenario with Eliquis and Entresto in a $9,996 annual drug bill comparison across three Part D plans: once your drug spend approaches five figures, the $2,000 cap is the single biggest variable in your plan choice.
GLP-1 Weight Loss Drugs on Medicare: The New Coupon Trap Hiding in Plain Sight
KFF Health News reported this month on a significant development: a new program called Foundayo may soon give Medicare beneficiaries access to discounted Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss. This matters because most Part D plans currently don't cover Wegovy or Zepbound for weight loss purposes — they may cover Ozempic for Type 2 diabetes, but obesity as the sole diagnosis typically doesn't qualify for Part D coverage.
The current landscape for a Medicare beneficiary wanting a GLP-1 for weight management:
| Drug | Without Coverage | Via Part D (if covered under diabetes diagnosis) | Via Foundayo / Bridge Program |
|---|---|---|---|
| Wegovy 2.4mg | ~$550–$650/mo | Not covered for weight loss on most plans | Projected discount pricing (details still developing) |
| Zepbound 15mg | ~$550–$650/mo | Not covered for weight loss on most plans | Projected discount pricing (details still developing) |
| Ozempic 1mg (diabetes diagnosis) | ~$800+ retail | $30–$120/mo on Tier 3–4 plans | N/A |
The critical question for anyone considering Foundayo or similar bridge access programs is the same one we just answered for GoodRx: do payments through this program count toward your Part D TrOOP?
Based on current program structure, outside-of-Part-D payments typically do not count toward TrOOP. If you're taking Ozempic through your Part D plan for diabetes at $75/month, those payments are building toward your $2,000 cap. If you're separately paying $350/month through a bridge program for Wegovy for weight loss, that $350 is not.
The moment Medicare formally covers GLP-1 drugs for obesity through Part D — which is an active policy conversation — that calculus changes entirely. Our breakdown of Ozempic and GLP-1 Part D costs across multiple plans covers which plans currently cover semaglutide and tirzepatide under diabetes vs. obesity diagnoses, and what the annual cost difference looks like.
The 2026 Plan Design Parameters That Change Your Coupon Math
Based on Pelandri's analysis of the plan-defaults dataset (30 rows of CMS benchmark plan design parameters) and cms-marketplace-plans data (4,080 rows of active plan filings), three changes between 2025 and 2026 directly affect whether a coupon beats your Part D plan:
- Part D deductible rose to $590 in 2026 (up from $545 in 2025) — meaning you pay more before copay rates kick in, which changes the early-year calculus for brand drugs
- The $2,000 OOP cap is now fully implemented, replacing the old catastrophic phase structure — this is a real ceiling with real consequences for anyone using expensive brand drugs
- IRA-negotiated drug TrOOP counting now includes manufacturer price concessions — for drugs like Eliquis, both your copay payment AND the manufacturer's discount contribution count toward your $2,000 cap, meaning you hit the ceiling faster than in prior years
That last point is consequential. Because Eliquis is negotiated under the IRA, your effective TrOOP credit per fill is higher than your out-of-pocket copay alone suggests. Using a coupon instead strips you of that credit entirely.
Pelandri's bls-medical-cpi dataset (1,080 rows of BLS medical price index data) also shows that prescription drug inflation has been running unevenly across drug categories — generic drug prices have remained largely flat, while specialty and brand drug prices have continued rising in the 5–12% annual range for non-negotiated products. That gap between stable generics and rising brands is precisely why the coupon math changes depending on which specific drugs are on your list. The KFF reporting captures this unevenness well: "Some prices dropped. Many others shot up" is not a rhetorical flourish — it's an accurate description of a bifurcated formulary landscape.
For a full cost comparison of how formulary tiers affect your real annual bill across plans, this breakdown of rosuvastatin on two different Part D plans shows how the same molecule can cost $240/year on one plan and $935/year on another — purely based on tier placement.
What to Actually Do Before Open Enrollment
Open Enrollment for 2027 coverage runs October 15 – December 7, 2026. That's five months out — but if you're currently paying more than you should because of coupon use or a mismatched plan, there are mid-year steps worth taking:
- Pull your current Part D Explanation of Benefits (EOB) — it shows your year-to-date TrOOP and which prescriptions were processed through insurance vs. paid out-of-pocket
- Identify any drugs you've been getting via coupon — check whether those same drugs are on your current plan's formulary and at what tier
- Calculate the full-year coupon cost vs. the full-year Part D cost including premium, deductible, and all copays — not just monthly copay vs. coupon price
- Check whether your drugs are IRA-negotiated — Eliquis, Jardiance, Entresto, Imbruvica, and others have Maximum Fair Prices that directly lower your Part D exposure and accelerate your path to the $2,000 cap
- If you take GLP-1 drugs, verify the diagnosis under which they're processed — diabetes diagnoses may qualify for Part D coverage; weight loss typically does not yet
If this analysis involves three or more drugs, a mix of generics and brands, and decisions about preferred vs. non-preferred pharmacies, the math gets genuinely complex — Pelandri is built to run it for your specific drug list, your pharmacy, and your ZIP code, producing a total annual cost that includes everything from deductible through cap. The coupon at the pharmacy counter is a number. Your actual annual cost is a calculation. Those are two very different things.
Sources
- That Discount at the Pharmacy Counter May Pack Hidden Costs — KFF Medicare
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up. — KFF Medicare
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know — KFF Medicare
- Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support — KFF Medicare